Učitavanje...
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Many studies have shown that genetic polymorphisms of the CYP2C9 gene contribute to some of the variability (around 20%) in warfarin dose requirements and therapeutic response to the drug. It is also clear that this effect must be elicited through difference...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Blackwell Science Inc
2007
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2000610/ https://ncbi.nlm.nih.gov/pubmed/17298479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02850.x |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|